Lenvatinib Mesylate and Rifadin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

The pharmacokinetics of lenvatinib are not significantly altered by rifampin, which acts as an inhibitor of P-glycoprotein (P-gp) during acute administration and an inducer of both P-gp and CYP450 3A4 during chronic administration. Following single-dose coadministration of lenvatinib 24 mg and rifampin 600 mg, lenvatinib peak plasma concentration (Cmax) increased by 33% and systemic exposure (AUC) increased by 31% compared to administration of lenvatinib alone. When a single 24 mg dose of lenvatinib was administered on day 15 of chronic rifampin dosing (600 mg/day for 21 days), lenvatinib AUC decreased by just 18% while Cmax did not change.

Lenvatinib Mesylate

Generic Name: lenvatinib

Brand name: Lenvima, Lenvima 8 mg daily-dose, Lenvima 20 mg daily-dose, Lenvima 12 mg daily-dose

Synonyms: Lenvatinib

What is Lenvatinib Mesylate?

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rifadin?